Back to results
US 2022/0008530 A1Published application
MERS-CoV VACCINE COMPOSITION
AssigneeKing Abdulaziz University
InventorAnwar M. HASHEM
Life of this patent
Estimating the term…
Abstract
An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
Claims8
A vaccine composition for Middle East respiratory syndrome coronavirus (MERS-CoV), comprising:
- a polysorbate carrier,
- albumin,
- an aqueous buffer solution, and
- a polypeptide that comprises at least one receptor-binding domain, immunogenic fragment, or epitope of S1 polypeptide of MERS-CoV, at least one trimerization motif, and at least one ligand for CD40;
- wherein the at least one trimerization motif comprises the amino acid sequence of SEQ ID NO:
- 6;
- or
- wherein the CD40 ligand is human CD40L comprising the sequence of SEQ ID NO:
- 23 or a sequence that is at least 70% identical thereto, or a CD40-binding fragment thereof;
- or
- wherein the CD40 ligand is camelid or human CD40L comprising the sequence of SEQ ID NO:
- 25 or 27 or a sequence that is at least 70% identical thereto, or a CD40-binding fragment thereof.
9 more elements
8-20. (canceled)
Dependencies are inferred from the claim text.